MKI67 and neoplasm: The anti-tumor effect of the concurrent ERK5 and CDK5 inhibition was due to decreased proliferation as shown by the decrease in Ki-67, a cell proliferation marker and increased cell death as shown by the increased number of Tunel-positive cells, a marker of apoptosis (Fig. 3C,D).